Audentes Therapeutics Company Profile (NASDAQ:BOLD)

About Audentes Therapeutics (NASDAQ:BOLD)

Audentes Therapeutics logoAudentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company's subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BOLD
  • CUSIP: N/A
  • Web: www.audentestx.com
Capitalization:
  • Market Cap: $553.69 million
  • Outstanding Shares: 27,726,000
Average Prices:
  • 50 Day Moving Avg: $15.51
  • 200 Day Moving Avg: $16.08
  • 52 Week Range: $13.06 - $20.74
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.28
  • P/E Growth: -0.78
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $4.71 per share
  • Price / Book: 4.24
Profitability:
  • EBIDTA: ($65,340,000.00)
  • Return on Assets: -51.48%
Debt:
  • Current Ratio: 9.87%
  • Quick Ratio: 9.87%
Misc:
  • Average Volume: 149,220 shs.
  • Short Ratio: 3.8
 

Frequently Asked Questions for Audentes Therapeutics (NASDAQ:BOLD)

What is Audentes Therapeutics' stock symbol?

Audentes Therapeutics trades on the NASDAQ under the ticker symbol "BOLD."

How were Audentes Therapeutics' earnings last quarter?

Audentes Therapeutics, Inc. (NASDAQ:BOLD) released its quarterly earnings data on Thursday, May, 11th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.92) by $0.09. View Audentes Therapeutics' Earnings History.

Where is Audentes Therapeutics' stock going? Where will Audentes Therapeutics' stock price be in 2017?

3 brokerages have issued 1 year price objectives for Audentes Therapeutics' shares. Their forecasts range from $20.00 to $24.00. On average, they expect Audentes Therapeutics' stock price to reach $22.00 in the next year. View Analyst Ratings for Audentes Therapeutics.

Who are some of Audentes Therapeutics' key competitors?

Who are Audentes Therapeutics' key executives?

Audentes Therapeutics' management team includes the folowing people:

  • Jonathan Todd Silverstein J.D., Independent Chairman of the Board
  • Matthew R. Patterson, President, Chief Executive Officer, Co-Founder, Director
  • Thomas J. Schuetz M.D. Ph.D., Co-Founder, Independent Director
  • Thomas P. Soloway, Chief Financial Officer, Senior Vice President
  • Natalie C. Holles, Chief Operating Officer, Senior Vice President
  • David Nagler, Senior Vice President - Human Resources and Corporate Affairs
  • John Gray Ph.D., Senior Vice President - Research and Development
  • Mary Newman, Senior Vice President - Regulatory Affairs
  • Suyash Prasad, Senior Vice President, Chief Medical Officer
  • Jennifer Jarrett, Director

When did Audentes Therapeutics IPO?

(BOLD) raised $75 million in an initial public offering on Wednesday, July 20th 2016. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who owns Audentes Therapeutics stock?

Audentes Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FLYNN JAMES E (7.59%), Versant Venture Management LLC (8.25%), ADAGE CAPITAL PARTNERS GP, L.L.C. (5.62%), Redmile Group LLC (3.75%), RA Capital Management LLC (2.43%) and Alliancebernstein L.P. (2.23%). Company insiders that own Audentes Therapeutics stock include 5Am Partners Iii, Llc, James E Flynn, Louis G Lange, Orbimed Advisors Llc and Versant Ventures Iv, Llc. View Institutional Ownership Trends for Audentes Therapeutics.

Who sold Audentes Therapeutics stock? Who is selling Audentes Therapeutics stock?

Audentes Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., FMR LLC, JPMorgan Chase & Co., Redmile Group LLC, Morgan Stanley, ProShare Advisors LLC, Parametric Portfolio Associates LLC and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Audentes Therapeutics.

Who bought Audentes Therapeutics stock? Who is buying Audentes Therapeutics stock?

Audentes Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Spark Investment Management LLC, Vanguard Group Inc., TD Asset Management Inc., Citadel Advisors LLC, Wells Fargo & Company MN, Bank of New York Mellon Corp and Bank of America Corp DE. Company insiders that have bought Audentes Therapeutics stock in the last two years include 5Am Partners Iii, Llc, James E Flynn, Orbimed Advisors Llc and Versant Ventures Iv, Llc. View Insider Buying and Selling for Audentes Therapeutics.

How do I buy Audentes Therapeutics stock?

Shares of Audentes Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Audentes Therapeutics' stock price today?

One share of Audentes Therapeutics stock can currently be purchased for approximately $19.97.


MarketBeat Community Rating for Audentes Therapeutics (NASDAQ BOLD)
Community Ranking:  1.9 out of 5 ()
Outperform Votes:  29 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  77
MarketBeat's community ratings are surveys of what our community members think about Audentes Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Audentes Therapeutics (NASDAQ:BOLD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $22.00 (10.17% upside)

Analysts' Ratings History for Audentes Therapeutics (NASDAQ:BOLD)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017WedbushReiterated RatingOurperform$20.00LowView Rating Details
5/1/2017Leerink SwannInitiated CoverageOutperform$22.00LowView Rating Details
11/12/2016Piper Jaffray CompaniesSet Price TargetBuy$24.00N/AView Rating Details
8/15/2016Cowen and CompanyInitiated CoverageOutperformN/AView Rating Details
(Data available from 6/29/2015 forward)

Earnings

Earnings History for Audentes Therapeutics (NASDAQ:BOLD)
Earnings by Quarter for Audentes Therapeutics (NASDAQ:BOLD)
Earnings History by Quarter for Audentes Therapeutics (NASDAQ BOLD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2017Q1 2017($0.92)($0.83)ViewN/AView Earnings Details
3/9/201712/31/2016($0.75)($0.91)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.66)($0.94)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Audentes Therapeutics (NASDAQ:BOLD)
2017 EPS Consensus Estimate: ($3.13)
2018 EPS Consensus Estimate: ($3.22)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.93)($0.93)($0.93)
Q2 20172($0.84)($0.69)($0.77)
Q3 20172($0.86)($0.60)($0.73)
Q4 20172($0.87)($0.54)($0.71)
Q1 20181($0.78)($0.78)($0.78)
Q2 20181($0.80)($0.80)($0.80)
Q3 20181($0.81)($0.81)($0.81)
Q4 20181($0.83)($0.83)($0.83)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Audentes Therapeutics (NASDAQ:BOLD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Audentes Therapeutics (NASDAQ:BOLD)
Insider Ownership Percentage: 47.30%
Institutional Ownership Percentage: 57.61%
Insider Trades by Quarter for Audentes Therapeutics (NASDAQ:BOLD)
Institutional Ownership by Quarter for Audentes Therapeutics (NASDAQ:BOLD)
Insider Trades by Quarter for Audentes Therapeutics (NASDAQ:BOLD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/26/2017Louis G LangeDirectorSell15,000$19.78$296,700.00View SEC Filing  
4/24/20175Am Partners Iii, LlcInsiderBuy172,413$14.50$2,499,988.50View SEC Filing  
7/25/2016James E FlynnInsiderBuy400,000$15.00$6,000,000.00View SEC Filing  
7/25/2016Orbimed Advisors LlcDirectorBuy33,334$15.00$500,010.00View SEC Filing  
7/25/2016Versant Ventures Iv, LlcMajor ShareholderBuy35,000$15.00$525,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Audentes Therapeutics (NASDAQ:BOLD)
Latest Headlines for Audentes Therapeutics (NASDAQ:BOLD)
Source:
DateHeadline
americanbankingnews.com logoAudentes Therapeutics, Inc. (BOLD) Director Louis G. Lange Sells 15,000 Shares
www.americanbankingnews.com - June 28 at 7:40 PM
finance.yahoo.com logoAudentes Therapeutics Announces Participation in Upcoming Investor Conferences
finance.yahoo.com - June 28 at 4:42 PM
americanbankingnews.com logoBrokerages Expect Audentes Therapeutics, Inc. (BOLD) to Post ($0.79) Earnings Per Share
www.americanbankingnews.com - June 21 at 6:15 PM
finance.yahoo.com logoAudentes Therapeutics Appoints Jennifer Jarrett to Board of Directors
finance.yahoo.com - June 13 at 1:00 PM
americanbankingnews.com logoZacks: Analysts Anticipate Audentes Therapeutics, Inc. (BOLD) Will Announce Earnings of -$0.79 Per Share
www.americanbankingnews.com - June 12 at 10:22 PM
americanbankingnews.com logoBrokerages Expect Audentes Therapeutics Inc (BOLD) to Post ($0.76) EPS
www.americanbankingnews.com - June 2 at 12:30 AM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Short Interest Update
www.americanbankingnews.com - May 28 at 8:20 PM
finance.yahoo.com logoWhy Audentes Therapeutics (BOLD) Could Be Positioned for a Surge
finance.yahoo.com - May 19 at 3:56 PM
americanbankingnews.com logoQ2 2017 EPS Estimates for Audentes Therapeutics Inc Lifted by Analyst (BOLD)
www.americanbankingnews.com - May 17 at 8:08 AM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Expected to Post Earnings of -$0.82 Per Share
www.americanbankingnews.com - May 16 at 8:24 AM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Receives Ourperform Rating from Wedbush
www.americanbankingnews.com - May 15 at 9:34 PM
reuters.com logoBRIEF-Audentes Therapeutics qtrly loss per share $0.83
www.reuters.com - May 13 at 2:36 AM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 12 at 12:56 PM
finance.yahoo.com logoAudentes Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - May 11 at 9:14 AM
finance.yahoo.com logoAudentes Therapeutics reports 1Q loss
finance.yahoo.com - May 11 at 9:14 AM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 10 at 5:22 PM
americanbankingnews.com logo Audentes Therapeutics Inc (BOLD) Given Consensus Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - May 9 at 6:38 PM
streetinsider.com logoAudentes Therapeutics (BOLD) Names John T. Gray, Ph.D. as SVP and Chief Scientific Officer
www.streetinsider.com - May 8 at 8:54 PM
finance.yahoo.com logoAudentes Therapeutics Announces Appointment of John T. Gray, Ph.D. to Senior Vice President and Chief Scientific Officer
finance.yahoo.com - May 8 at 10:26 AM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Expected to Post Q1 2017 Earnings of ($0.93) Per Share
www.americanbankingnews.com - May 4 at 8:04 AM
streetinsider.com logoAudentes Therapeutics (BOLD) Announces Presentation of Data at ASGCT
www.streetinsider.com - May 4 at 2:04 AM
finance.yahoo.com logoAudentes Therapeutics Announces Presentation of Data at the American Society of Gene and Cell Therapy Annual Meeting
finance.yahoo.com - May 3 at 9:26 AM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Coverage Initiated by Analysts at Leerink Swann
www.americanbankingnews.com - May 2 at 12:04 AM
americanbankingnews.com logoInsider Buying: Audentes Therapeutics Inc (BOLD) Insider Buys 172,413 Shares of Stock
www.americanbankingnews.com - April 26 at 10:52 PM
americanbankingnews.com logo-$0.92 EPS Expected for Audentes Therapeutics Inc (BOLD) This Quarter
www.americanbankingnews.com - April 25 at 5:18 PM
americanbankingnews.com logo Audentes Therapeutics Inc (BOLD) Given Average Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - April 24 at 4:42 PM
streetinsider.com logoAudentes Therapeutics (BOLD) Prices 5.2M Share Offering at $14.50/Sh
www.streetinsider.com - April 19 at 1:12 PM
finance.yahoo.com logoAudentes Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - April 19 at 1:12 PM
finance.yahoo.com logoAudentes Therapeutics Gears Up for Secondary Offering
finance.yahoo.com - April 19 at 1:12 PM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 5:57 PM
finance.yahoo.com logoAudentes Therapeutics to Present at the ARM 5th Annual Cell & Gene Therapy Investor Day
finance.yahoo.com - April 17 at 12:26 PM
americanbankingnews.com logoZacks Investment Research Downgrades Audentes Therapeutics Inc (BOLD) to Sell
www.americanbankingnews.com - April 11 at 4:34 PM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 4 at 6:37 PM
us.rd.yahoo.com logoAudentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT132 to Treat X-Linked Myotubular Myopathy
us.rd.yahoo.com - April 3 at 4:24 PM
americanbankingnews.com logoAudentes Therapeutics Inc (BOLD) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 24 at 7:22 PM
americanbankingnews.com logo Audentes Therapeutics Inc (BOLD) Given Consensus Rating of "" by Analysts
www.americanbankingnews.com - March 24 at 12:23 PM
finance.yahoo.com logoAudentes Therapeutics Announces Presentation Of Data From RECENSUS, A Medical Chart Review Of Patients With X-Linked Myotubular Myopathy (XLMTM)
finance.yahoo.com - March 20 at 11:52 AM
finance.yahoo.com logoAUDENTES THERAPEUTICS, INC. Financials
finance.yahoo.com - March 16 at 3:40 PM
americanbankingnews.com logoFY2021 Earnings Estimate for Audentes Therapeutics Inc (BOLD) Issued By Wedbush
www.americanbankingnews.com - March 13 at 2:48 PM
biz.yahoo.com logoAUDENTES THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 13 at 11:49 AM
finance.yahoo.com logoAudentes Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
finance.yahoo.com - March 9 at 4:34 PM
finance.yahoo.com logoAudentes Therapeutics Announces Commencement of LUSTRO, a Clinical Assessment and Phase 1/2 Run-in Study of Patients with Crigler-Najjar Syndrome
finance.yahoo.com - March 1 at 9:16 AM
us.rd.yahoo.com logoAudentes Therapeutics Announces FDA Clearance of Investigational New Drug Application for AT342 to Treat Crigler-Najjar Syndrome
us.rd.yahoo.com - February 1 at 4:13 PM
us.rd.yahoo.com logo8:01 am Audentes Therapeutics announces that the FDA has cleared the investigational new drug (IND) application for AT342
us.rd.yahoo.com - February 1 at 4:13 PM
streetinsider.com logoAudentes Therapeutics (BOLD) Receives FDA Clearance of IND Application for AT342 to Treat Crigler-Najjar Syndrome
www.streetinsider.com - February 1 at 4:13 PM
finance.yahoo.com logoAudentes Therapeutics Provides Full Year 2017 Strategic Outlook and Financial Guidance
finance.yahoo.com - January 9 at 5:03 PM
finance.yahoo.com logo8:04 am Audentes Therapeutics's cash position is projected to fund operations into late 2018; provides FY17 milestones
finance.yahoo.com - January 9 at 5:03 PM
finance.yahoo.com logoAudentes Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 4:57 PM
biz.yahoo.com logoAUDENTES THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - December 13 at 4:40 PM
finance.yahoo.com logoAudentes Therapeutics Announces Initiation of Large-scale cGMP Production at its Gene Therapy Manufacturing Facility
finance.yahoo.com - November 30 at 5:43 AM

Social

Chart

Audentes Therapeutics (BOLD) Chart for Thursday, June, 29, 2017

This page was last updated on 6/29/2017 by MarketBeat.com Staff